StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
381
This month
4
This year
37
Publishing Date
2024 - 03 - 28
3
2024 - 02 - 14
3
2023 - 11 - 29
3
2023 - 11 - 27
3
2023 - 10 - 27
2
2023 - 10 - 18
2
2023 - 10 - 02
2
2023 - 09 - 13
3
2023 - 08 - 30
2
2023 - 08 - 21
2
2023 - 08 - 01
2
2023 - 05 - 30
2
2023 - 05 - 01
2
2023 - 04 - 21
3
2023 - 04 - 03
2
2023 - 03 - 09
2
2023 - 03 - 07
3
2023 - 03 - 02
2
2023 - 02 - 27
3
2023 - 02 - 23
2
2023 - 02 - 21
2
2023 - 02 - 06
2
2023 - 01 - 23
2
2023 - 01 - 19
2
2023 - 01 - 06
3
2022 - 12 - 22
2
2022 - 12 - 21
3
2022 - 12 - 01
2
2022 - 11 - 21
2
2022 - 10 - 12
3
2022 - 09 - 29
2
2022 - 08 - 22
4
2022 - 08 - 03
3
2022 - 07 - 25
2
2022 - 07 - 19
4
2022 - 07 - 18
6
2022 - 06 - 21
2
2022 - 06 - 08
2
2022 - 05 - 31
5
2022 - 05 - 02
4
2022 - 03 - 31
2
2022 - 02 - 22
2
2022 - 02 - 15
2
2022 - 01 - 31
2
2022 - 01 - 24
3
2022 - 01 - 20
2
2021 - 12 - 29
3
2021 - 12 - 22
2
2021 - 12 - 20
2
2021 - 12 - 14
2
2021 - 12 - 06
2
2021 - 11 - 30
2
2021 - 11 - 29
3
2021 - 10 - 19
3
2021 - 10 - 01
2
2021 - 08 - 23
2
2021 - 07 - 14
2
2021 - 06 - 03
2
2021 - 05 - 03
2
2021 - 01 - 04
3
Sector
Communications
6
Consumer non-durables
1
Health care and social assistance
5
Health services
2
Health technology
311
Manufacturing
30
N/a
10
Non-energy minerals
1
Process industries
5
Producer manufacturing
7
Professional, scientific, and technical services
5
Retail trade
1
Tags
Alliances
98
Als
91
Application
381
Approval
371
Biotech
86
Biotech-bay
113
Biotech-beach
124
Cancer
622
Cell
87
Chmp
97
Clearance
139
Clinical-trials-phase-ii
204
Clinical-trials-phase-iii
140
Collaboration
98
Covid
177
Covid-19
139
Designation
429
Diabetes
94
Disease
531
Drug
573
Enroll
86
Europe
181
Events
96
Fast track designation
107
Fda
946
Fda-approvals
113
Food
87
Genetown
147
Global
213
Granted
154
Growth
158
Health
109
License
124
Market
358
Meeting
104
N/a
3128
New drug
97
Patent
147
Pharm-country
172
Pharma
91
Pharmaceuticals
248
Phase 1
179
Phase 2
249
Phase 2b
114
Phase 3
195
Positive
429
Potential
275
Preclinical
107
Report
153
Research
544
Results
241
Review
91
Study
321
Submission
87
Therapeutics
549
Therapy
350
Topline
108
Treatment
5293
Trial
859
Water
92
Entities
3m company
2
Abbvie inc.
6
Acadia pharmaceuticals inc.
5
Acer therapeutics inc.
2
Agios pharmaceuticals, inc.
2
Aldeyra therapeutics, inc.
5
Alnylam pharmaceuticals, inc.
10
Altamira therapeutics ltd
2
Amgen inc.
2
Amneal pharmaceuticals, inc.
2
Amylyx pharmaceuticals, inc.
6
Annovis bio, inc.
2
Arcutis biotherapeutics, inc.
6
Astellas pharma inc
5
Atara biotherapeutics, inc.
2
Axsome therapeutics, inc.
3
Bausch health companies inc.
2
Biogen inc.
9
Blueprint medicines corporation
3
Brainstorm cell therapeutics inc.
2
Bridgebio pharma, inc.
3
Bristol-myers squibb company
11
Cabaletta bio, inc.
4
Calliditas therapeutics ab
4
Citius pharmaceuticals, inc.
4
Clearmind medicine inc.
4
Clearside biomedical, inc.
2
Coherus biosciences, inc.
2
Cyclo therapeutics inc - class a
2
Cymabay therapeutics inc.
2
Dupont de nemours, inc.
2
Dyne therapeutics, inc.
2
Eagle pharmaceuticals, inc.
3
Eli lilly and company
10
Fortress biotech, inc.
5
Genmab a/s
5
Incyte corporation
9
Intellia therapeutics, inc.
3
Jaguar health, inc.
3
Johnson & johnson
13
Karuna therapeutics, inc.
4
Madrigal pharmaceuticals, inc.
4
Merck & company, inc.
4
Minerva neurosciences, inc
5
Nrx pharmaceuticals inc
3
Nuvation bio inc - class a
4
Orange
6
Outlook therapeutics, inc.
5
Passage bio, inc.
3
Pfizer, inc.
6
Reata pharmaceuticals, inc.
3
Regeneron pharmaceuticals, inc.
3
Sage therapeutics, inc.
4
Sana biotechnology inc
3
Sanofi
17
Scisparc ltd
3
Soligenix, inc.
4
Springworks therapeutics, inc.
4
Travere therapeutics inc.
4
Verrica pharmaceuticals inc.
5
Symbols
ABBV
6
ACAD
5
ACER
2
AGIO
2
ALDX
5
ALNY
10
ALPMF
5
ALPMY
5
AMGN
2
AMLX
6
AMRX
2
ANVS
2
ARQT
6
ATRA
2
AXSM
3
BBIO
3
BCLI
2
BHC
2
BIIB
9
BMY
11
BPMC
3
CABA
4
CALT
4
CBAY
2
CHRS
2
CLSD
2
CMND
4
CTXR
4
CYTH
2
CYTO
2
EGRX
3
FBIO
5
FNCTF
6
GMAB
5
GNMSF
5
INCY
9
JAGX
3
JNJ
13
KRTX
4
LLY
10
MDGL
4
MRK
4
NERV
5
NRXP
3
NTLA
3
NUVB
4
OTLK
5
PASG
3
PFE
6
REGN
3
RETA
3
SAGE
4
SANA
3
SNGX
4
SNY
17
SNYNF
17
SPRC
3
SWTX
4
TVTX
4
VRCA
5
Exchanges
Amex
6
Nasdaq
322
Nyse
80
Crawled Date
2024 - 03 - 28
3
2024 - 02 - 14
3
2023 - 11 - 29
3
2023 - 11 - 27
3
2023 - 09 - 13
3
2023 - 08 - 30
2
2023 - 08 - 21
2
2023 - 08 - 01
2
2023 - 05 - 30
2
2023 - 05 - 01
2
2023 - 04 - 21
3
2023 - 04 - 03
2
2023 - 03 - 09
2
2023 - 03 - 07
3
2023 - 03 - 02
2
2023 - 02 - 27
3
2023 - 02 - 23
2
2023 - 02 - 21
2
2023 - 02 - 06
2
2023 - 01 - 23
2
2023 - 01 - 19
2
2023 - 01 - 06
3
2022 - 12 - 22
2
2022 - 12 - 21
3
2022 - 12 - 01
2
2022 - 11 - 29
2
2022 - 11 - 21
2
2022 - 10 - 12
3
2022 - 09 - 29
2
2022 - 08 - 22
4
2022 - 08 - 03
3
2022 - 07 - 25
2
2022 - 07 - 20
3
2022 - 07 - 19
3
2022 - 07 - 18
5
2022 - 06 - 21
2
2022 - 06 - 08
2
2022 - 05 - 31
5
2022 - 05 - 02
4
2022 - 03 - 31
2
2022 - 02 - 22
2
2022 - 02 - 15
2
2022 - 01 - 31
2
2022 - 01 - 24
2
2022 - 01 - 20
2
2021 - 12 - 29
3
2021 - 12 - 22
2
2021 - 12 - 20
2
2021 - 12 - 14
2
2021 - 12 - 06
2
2021 - 11 - 30
2
2021 - 11 - 29
3
2021 - 10 - 19
3
2021 - 10 - 01
2
2021 - 08 - 23
2
2021 - 07 - 14
2
2021 - 06 - 03
2
2021 - 05 - 03
2
2021 - 01 - 04
3
2020 - 12 - 01
2
Crawled Time
00:00
12
00:20
1
01:00
4
02:00
3
04:00
1
05:00
3
06:00
7
07:00
10
08:00
4
08:20
2
09:00
6
10:00
1
11:00
19
12:00
65
12:01
2
12:03
1
12:06
1
12:15
2
12:20
15
12:30
15
13:00
52
13:15
1
13:20
11
13:30
9
13:35
1
14:00
38
14:01
1
14:03
1
14:20
2
14:30
5
15:00
15
15:01
1
15:15
1
15:20
3
15:30
7
15:56
1
16:00
3
16:20
1
17:00
8
18:00
2
19:00
8
20:00
7
21:00
10
21:03
1
22:00
9
22:02
1
22:15
1
23:00
7
Source
alteritytherapeutics.com
1
arcutis.com
1
bridgebio.com
2
investor.aveooncology.com
1
jaguarhealth.gcs-web.com
3
www.4dpharmaplc.com
1
www.anavex.com
1
www.biospace.com
193
www.globenewswire.com
116
www.hepionpharma.com
1
www.prnewswire.com
60
www.zailaboratory.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
tags :
Application
save search
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Published:
2024-04-10
(Crawled : 12:00)
- globenewswire.com
CMND
|
$1.185
-2.87%
-2.95%
1M
|
n/a
|
-7.58%
|
O:
-3.03%
H:
7.03%
C:
-0.78%
patent
disorders
treatment
for
application
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Published:
2024-04-08
(Crawled : 09:00)
- biospace.com/
CALT
|
$18.8
5.62%
5.32%
6.8K
|
Health Technology
|
-17.71%
|
O:
-1.06%
H:
3.5%
C:
0.51%
patent
cancer
treatment
for
application
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
Published:
2024-04-04
(Crawled : 23:00)
- biospace.com/
DTIL
|
$11.5
-10.65%
-11.91%
220K
|
Health Technology
|
-16.65%
|
O:
-2.33%
H:
1.64%
C:
-4.91%
ecur-506
fda
drug
treatment
clearance
for
application
trial
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
Published:
2024-04-02
(Crawled : 11:00)
- biospace.com/
RCKT
M
|
$23.7
-2.27%
-2.32%
640K
|
Health Technology
|
-9.07%
|
O:
-1.76%
H:
0.0%
C:
-1.91%
anemia
authorization
treatment
pharmaceuticals
application
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Published:
2024-03-31
(Crawled : 00:00)
- prnewswire.com
BIIB
|
$192.13
-1.55%
-1.57%
1.3M
|
Health Technology
|
-10.23%
|
O:
-0.88%
H:
0.0%
C:
0.0%
leqembi
fda
disease
license
treatment
alzheimer's
application
submission
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published:
2024-03-28
(Crawled : 15:00)
- prnewswire.com
ALPMY
|
$9.34
-1.11%
690K
|
Manufacturing
|
-14.63%
|
O:
0.82%
H:
0.0%
C:
-2.54%
keytruda
license
bladder
cancer
treatment
medical
application
advanced
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
Published:
2024-03-28
(Crawled : 13:30)
- globenewswire.com
FBLG
|
$9.57
-12.92%
-14.84%
140K
|
|
-6.47%
|
O:
-1.87%
H:
0.0%
C:
-6.24%
patent
lupus
treatment
application
technology
potential
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
Published:
2024-03-28
(Crawled : 11:00)
- globenewswire.com
MIST
|
$1.74
-1.14%
-1.15%
110K
|
Health Technology
|
-2.22%
|
O:
4.44%
H:
0.0%
C:
0.0%
etripamil
drug
tachycardia
resubmission
treatment
pharmaceuticals
application
milestone
Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE™ Platform for the Treatment of Paroxysmal Atrial Fibrillation
Published:
2024-03-25
(Crawled : 12:00)
- prnewswire.com
JNJ
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-7.14%
|
O:
0.04%
H:
0.0%
C:
0.0%
fda
approval
treatment
application
platform
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published:
2024-03-21
(Crawled : 21:00)
- biospace.com/
VRTX
|
$393.1
-0.27%
-0.27%
880K
|
Health Technology
|
-4.35%
|
O:
0.85%
H:
0.88%
C:
0.02%
vx-407
fda
drug
disease
kidney
treatment
clearance
application
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
Published:
2024-03-19
(Crawled : 12:00)
- globenewswire.com
CLPT
|
$5.57
-0.18%
-0.18%
140K
|
Health Technology
|
-21.07%
|
O:
0.0%
H:
0.99%
C:
-1.27%
fda
license
treatment
application
therapeutics
submission
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Published:
2024-03-18
(Crawled : 12:30)
- globenewswire.com
DERM
|
$3.85
1.32%
1.3%
130K
|
|
11.76%
|
O:
2.94%
H:
14.57%
C:
6.86%
FBIO
|
$1.79
1.7%
1.68%
240K
|
Health Technology
|
-9.04%
|
O:
3.36%
H:
0.5%
C:
-4.0%
dfd-29
fda
drug
corporation
treatment
medical
application
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Published:
2024-03-11
(Crawled : 11:00)
- globenewswire.com
TVTX
|
$5.99
-2.6%
-2.67%
1.3M
|
Health Technology
|
-28.98%
|
O:
-0.81%
H:
1.51%
C:
-6.98%
filspari
nephropathy
drug
approval
food
treatment
application
therapeutics
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Published:
2024-03-05
(Crawled : 13:00)
- globenewswire.com
MDGL
M
|
$228.46
-1.94%
-1.98%
250K
|
Health Technology
|
-5.51%
|
O:
-0.86%
H:
2.04%
C:
1.66%
liver
authorization
treatment
fibrosis
pharmaceuticals
ema
application
AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published:
2024-03-05
(Crawled : 08:00)
- biospace.com/
SNY
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-2.4%
|
O:
1.17%
H:
0.0%
C:
0.0%
lung
drug
cancer
treatment
application
therapeutics
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
Published:
2024-03-04
(Crawled : 13:00)
- globenewswire.com
CBAY
|
$32.48
0.03%
8.4M
|
Health Technology
|
0.68%
|
O:
-0.03%
H:
0.19%
C:
-0.19%
review
authorization
treatment
application
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
Published:
2024-03-04
(Crawled : 12:00)
- globenewswire.com
SWTX
|
$44.12
1.66%
1.63%
840K
|
Health Technology
|
-14.92%
|
O:
0.49%
H:
0.12%
C:
-2.95%
fda
drug
children
treatment
application
therapeutics
submission
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
Published:
2024-02-29
(Crawled : 13:30)
- globenewswire.com
ICPT
|
$19.0
-0.05%
4M
|
Health Technology
|
Email alert
Add to watchlist
ocaliva
fda
drug
treatment
application
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Published:
2024-02-29
(Crawled : 13:30)
- globenewswire.com
SWTX
|
$44.12
1.66%
1.63%
840K
|
Health Technology
|
-10.72%
|
O:
2.2%
H:
1.21%
C:
-0.85%
tumors
authorization
treatment
application
therapeutics
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
Published:
2024-02-28
(Crawled : 13:00)
- globenewswire.com
APLT
|
$4.82
-6.41%
-6.85%
860K
|
Health Technology
|
-7.71%
|
O:
44.8%
H:
16.21%
C:
-8.42%
fda
drug
review
treatment
application
therapeutics
← Previous
1
2
3
4
5
6
7
8
9
…
19
20
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.